Abstract

The idea that infectious agents can induce autoimmune diseases in genetically susceptible subjects has been a matter of discussion for years. Moreover, increased incidence of autoimmune diseases and introduction of prophylactic vaccinations from early childhood suggest that these two trends are linked. In the medical literature and even non-professional media, case reports or events temporally related to vaccination are reported. It raises the issue of vaccination safety. In everyday practice medical professionals, physicians, rheumatologists and other specialists will be asked their opinion of vaccination safety. The decision should be made according to evidence-based medicine and the current state of knowledge. The purpose of this paper is to discuss a potential mechanism which links infections, vaccinations and autoimmunity. We present an overview of published case reports, especially of systemic connective tissue diseases temporally related to vaccination and results from case-nested studies. As yet, no conclusive evidence supports a causal relationship between vaccination and autoimmune diseases. It has to be determined whether the performed studies are sufficiently Epsteinasensitive to detect the link. The debate is ongoing, and new data may be required to explain the pathogenesis of autoimmunity. We would like to underscore the need for prophylactic vaccination in patients with autoimmune rheumatic diseases and to break down the myth that the vaccines are contraindicated in this target group.

References

• 1. Agmon-Levin N., Zafrir Y., Paz Z., Shilton T., Zadman-Goddard G.,Shoenfeld Y.: Ten cases of systemic lupus erythematosus related tohepatitis B vaccine. Lupus, 2009; 18: 1192-1197
  Google Scholar
• 2. Anders H.J., Zecher D., Pawar R.D., Patole P.: Molecular mechanismsof autoimmunity triggered by microbial infection. ArthritisRes. Ther., 2005; 7: 215-224
  Google Scholar
• 3. Anon.: Causality assessment of adverse events following immunization.Wkly. Epidemiol. Rec., 2001; 76: 85-89
  Google Scholar
• 4. Ascherio A., Zhang S.M., Hernán M.A., Olek M.J., Coplan P.M.,Brodovicz K., Walker A.M.: Hepatitis B vaccination and the risk ofmultiple sclerosis. N. Engl. J. Med., 2001; 344: 327-332
  Google Scholar
• 5. Ayvazian L.F., Badger T.L.: Disseminated lupus erythematosusoccurring among student nurses. N. Engl. J. Med., 1948; 239: 565-570
  Google Scholar
• 6. Belloni C., Avanzini M.A., De Silvestri A., Martinetti M., Pasi A.,Coslovich E., Autelli M., Masanti M.L., Cuccia M., Tinelli C., RondiniG., Lorini R.: No evidence of autoimmunity in 6-year-old childrenimmunized at birth with recombinant hepatitis B vaccine. Pediatrics,2002; 110: 1-4
  Google Scholar
• 7. Bengtsson C., Kapetanovic M.C., Kallberg H., Sverdrup B.,Nordmark B., Klareskog L., Alfredsson L., EIRA Study Group.:Common vaccinations among adults do not increase the risk ofdeveloping rheumatoid arthritis: results from the Swedish EIRAstudy. Ann. Rheum. Dis., 2010; 69: 1831-1833
  Google Scholar
• 8. Bishop W.B., Carlton R.F., Sanders L.L.: Diffuse vasculitis and deathafter hyperimmunization with pertussis vaccine. N. Engl. J. Med.,1966; 274; 616-619
  Google Scholar
• 9. Bitnum S., Daeschner C.W.Jr., Travis L.B., Dodge W.F., Hopps H.C.:Dermatomiositis. J. Pediatr., 1964; 64: 101-131
  Google Scholar
• 10. Confavreux C., Suissa S., Saddier P., Bourdès V., Vukusic S., Vaccinesin Multiple Sclerosis Study Group: Vaccinations and the riskof relapse in multiple sclerosis. Vaccines in Multiple Sclerosis StudyGroup. N. Engl. J. Med., 2001; 344: 319-326
  Google Scholar
• 11. Cooper G.S., Dooley M.A., Treadwell E.L., St Clair E.W., GilkesonG.S.: Risk factors for development of systemic lupus erythematosus:allergies, infections, and family history. J. Clin. Epidemiol.,2002; 55: 982-989
  Google Scholar
• 12. Crow M.K., Kirou K.: Interferon alpha in systemic lupus erythematosus.Curr. Opin. Rheumatol., 2004; 16: 541-547
  Google Scholar
• 13. Davidson A., Diamond B.: Autoimmune diseases. N. Engl. J. Med.,2001; 345: 340-350
  Google Scholar
• 14. De Carvalho J.F, Pereira R.M., Shoenfeld Y.: Systemic polyarteritisnodosa following hepatitis B vaccination. Eur. J. Int. Med.2008; 19: 575-578
  Google Scholar
• 15. Descamps D., Hardt K., Spiessens B., Izurieta P., Verstraeten T.,Breuer T., Dubin G.: Safety of human papillomavirus (HPV)-16/18AS04-adjuvanted vaccine for cervical cancer prevention: a pooledanalysis of 11 clinical trials. Hum. Vaccin, 2009; 5: 332-340
  Google Scholar
• 16. DeStefano F., Mullooly J.P., Okoro C.A., Chen R.T., Marcy S.M.,Ward J.I., Vadheim C.M., Black S.B., Shinefield H.R., Davis R.L., BohlkeK., Vaccine Safety Datalink Team: Childhood vaccinations, vaccinationtiming, and risk of type 1 diabetes mellitus. Paediatrics,2001; 108, E112
  Google Scholar
• 17. Dupont J., Altclas J., Lepetic A., Lombardo M., Vázquez V., SalgueiraC., Seigelchifer M., Arndtz N., Antunez E., von Eschen K.,Janowicz Z.: A controlled clinical trial comparing the safety and immunogenicityof a new adjuvanted hepatitis B vaccine with standardhepatitis B vaccine. Vaccine, 2006; 24; 7161-7174
  Google Scholar
• 18. Ehrengut W.: Dermatomyositis and vaccination. Lancet, 1978;1: 1040-1041
  Google Scholar
• 19. Fox R.A.: Disseminated lupus erythematosus: an allergic disease?Arch. Path., 1943; 36: 311-315
  Google Scholar
• 20. Gatto M., Agmon-Levin N., Soriano A., Manna R., Maoz-Segal R.,Kivity S., Doria A., Shoenfeld Y.: Human papilloma virus vaccine andsystemic lupus erythematosus. Clin. Rheumatol., 2013; 32: 1301-1307
  Google Scholar
• 21. Geier D.A., Geier M.R.: A one year follow up of chronic arthritisfollowing rubella and hepatitis B vaccination based upon analysisof the Vaccine Adverse Events Reporting System (VAERS) database.Clin. Exp. Rheumatol., 2002; 20, 767-771
  Google Scholar
• 22. Geier M.R., Geier D.A.: A case series of adverse events, positivere-challenge of symptoms, and events in identical twins followinghepatitis B vaccination: analysis of Vaccine Adverse Event ReportingSystem (VAERS) database and literature review. Clin. Exp. Rheumatol.,2004; 22: 749-755
  Google Scholar
• 23. Gross K., Combe C., Kruger K., Schattenkirchner M.: Arthritisafter hepatitis B vaccination: Report of three cases. Scan. J. Rheumatol.,1995; 24: 50-52
  Google Scholar
• 24. Guiserix J.: Systemic lupus erythematosus following hepatitisB vaccine. Nephron, 1996; 74: 441
  Google Scholar
• 25. Guthridge J.M., Cogman A., Merrill J.T., Macwana S., Bean K.M.,Powe T., Roberts V., James J.A., Chakravarty E.F.: Herpes zoster vaccinationin SLE: a pilot study of immunogenicity. J. Rheumatol.,2013; 40: 1875-1880
  Google Scholar
• 26. Harley J.B., Harley I.T., Guthridge J.M., James J.A.: The curiouslysuspicious: a role for Epstein-Barr virus in lupus. Lupus, 2006; 15:768-777
  Google Scholar
• 27. Heijstek M.W., de Bruin L.M.O., Bijl M., Borrow R., van der KlisF., Kone-Paut I., Fasth A., Minden K., Ravelli A., Abinun M., PileggiG.S., Borte M., Wulffraat N.M.: EULAR recommendations for vaccinationin pediatric patients with rheumatic diseases. Ann. Rheum.Dis., 2011; 70: 1704-1712
  Google Scholar
• 28. Jahnz-Rozyk K.: Pharmaco-economics of anti-influenza vaccinations.Pol. Merkur. Lekarski, 2003; 14: 679-681
  Google Scholar
• 29. Jarząb A., Skowicki M., Witkowska D.: Szczepionki podjednostkowe- antygeny, nośniki, metody koniugacji i rola adiuwantów.Postępy Hig. Med. Dośw., 2013; 67: 1128-1143
  Google Scholar
• 30. Jawad A.S.M., Scott D.G.: Immunisation triggering rheumatoidarthritis? Ann. Rheum. Dis., 1989; 48: 174
  Google Scholar
• 31. Kanzler H., Barrat F.J., Hessel E.M., Coffman R.L.: Therapeutictargeting of innate immunity with Toll-like receptor agonists andantagonists. Nat. Med., 2007; 13: 552-559
  Google Scholar
• 32. Karvonen M., Cepaitis Z., Tuomilehto J.: Association betweentype 1 diabetes and Haemophilus influenzae type b vaccination: birthcontrol study. Br. Med. J., 1999; 318: 1169-1172
  Google Scholar
• 33. Kass E., Straume S., Munthe E.: Dermatomyositis after B.C.Gvaccination. Lancet, 1978, 1: 772
  Google Scholar
• 34. Kovács G., Kaló Z., Jahnz-Rozyk K., Kyncl J., Csohan A., PistolA., Leleka M., Kipshakbaev R., Durand L., Macabeo B.: Medical andeconomic burden of influenza in the elderly population in centraland eastern European countries. Hum. Vaccin Immunother., 2014;10: 428-440
  Google Scholar
• 35. Kurland L.T., Molgaard C.A., Kurland E.M., Erdtmann F.J., StebbingG.E.: Lack of association of swine flu vaccine and rheumatoidarthritis. Mayo Clin. Proc., 1984; 59: 816-821
  Google Scholar
• 36. Lasky T., Terracciano G.J., Magder L., Koski C.L., Ballesteros M.,Nash D., Clark S., Haber P., Stolley P.D., Schonberger L.B., Chen R.T.:The Guillain-Barré syndrome and the 1993-1993 and 1993-1994 influenzavaccines. N. Engl. J. Med., 1998; 339: 1797-1802
  Google Scholar
• 37. Lis J., Jarząb A., Witkowska D.: Rola mimikry molekularnej w etiologii schorzeń o charakterze autoimmunizacyjnym. PostępyHig. Med. Dośw., 2012; 66: 745-791
  Google Scholar
• 38. Mader R., Narendran A., Lewtas J., Bykerk V., Goodman R.C.,Dickson J.R., Keystone E.C.: Systemic vasculitis following influenzavaccination: report of 3 cases and literature review. J. Rheumatol.,1993; 20: 1429-1431
  Google Scholar
• 39. Maillefert J.F., Sibilia J., Toussirot E., Vignon E., Eschard J.P., LorcerieB., Juvin R., Parchin-Geneste N., Piroth C., Wendling D., KuntzJ.L., Tavernier C., Gaudin P.: Rheumatic disorders developed afterhepatitis B vaccination. Rheumatology, 1999; 38: 978-983
  Google Scholar
• 40. McClain M.T., Heinlen L.D., Dennis G.J., Roebuck J., Harley J.B.,James J.A.: Early events in lupus humoral autoimmunity suggestinitiation through molecular mimicry. Nat. Med., 2005; 11: 85-89
  Google Scholar
• 41. Mukerji B.: Myositis and vasculitis following vaccinations. Ann.Rheum. Dis., 2002; ABO199
  Google Scholar
• 42. Muniz Caldas C.A., Freire de Carvalho J.: The role of environmentalfactors in the pathogenesis of non-organ-specific autoimmunediseases. Best Prac. Res. Clin Rheumatol., 2012; 26: 5-11
  Google Scholar
• 43. Older S.A., Battafarano D.F., Enzenauer R.J., Krieg A.M.: Can immunizationprecipitate connective tissue disease? Report of 5 casesof systemic lupus erythematosus and review of the literature. Semin.Arthrits Rheum., 1999; 29: 131-139
  Google Scholar
• 44. Pope J.E., Stevens A., Howson W., Bell D.A.: The development ofrheumatoid arthritis after recombinant hepatitis B vaccination. J.Rheumatol., 1998; 25: 1687-1693
  Google Scholar
• 45. Schattner A.: Consequence or coincidence? The occurrence,pathogenesis and significance of autoimmune manifestations afterviral vaccines. Vaccine, 2005; 23: 3876-3886
  Google Scholar
• 46. Shoenfeld Y., Agmon-Levin N.: ’ASIA’ – autoimmune/inflammatorysyndrome induced by adjuvants. J. Autoimmun., 2011; 36: 4-8
  Google Scholar
• 47. Shoenfeld Y., Maślinska M.: Autoimmune (auto-inflammatory)syndrome induced by adjuvants – ASIA. Reumatologia, 2013;51: 101-107
  Google Scholar
• 48. Symmons D.P., Chakravarty K.: Can immunisation trigger rheumatoidarthritis? Ann. Rheum. Dis., 1993; 52: 843-844
  Google Scholar
• 49. Toussirot E., Roudier J.: Epstein-Barr virus in autoimmune diseases.Best Pract. Res. Clin. Rheumatol., 2008; 22: 883-896
  Google Scholar
• 50. Tse K., Horner A.A.: Update on toll-like receptor directed therapiesfor human disease. Ann. Rheum. Dis., 2007; 66, Suppl. 3: iii77–iii80
  Google Scholar
• 51. Tudela P., Marti S., Bonal J.: Systemic lupus erythematosus andvaccination against hepatitis B. Nephron, 1992; 62: 236
  Google Scholar
• 52. van Assen S., Agmon-Levin N., Elkayam O., Cervera R., DoranM.F., Dougados M., Emery P., Geborek P., Ioannidis J.P.A., Jayne D.R.,Kallenberg C.G., Müller-Ladner U., Shoenfeld Y., Stojanovich L., ValesiniG., Wulffraat N.M., Bijl M.: EULAR recommendations for vaccinationin adult patients with autoimmune inflammatory rheumaticdiseases. Ann. Rheum. Dis., 2011; 70: 414-422
  Google Scholar
• 53. Vautier G., Carty J.E.: Acute sero-positive rheumatoid arthritisoccurring after hepatitis vaccination. Br. J. Rheumatol., 1994; 33: 991
  Google Scholar
• 54. Verstraeten T., Descamps D., David M.P., Zahaf T., Hardt K., IzurietaP., Dubin G., Breuer T.: Analysis of adverse events of potentialautoimmune aetiology in a large integrated safety database of AS04adjuvaned vaccines. Vaccine, 2008; 26: 6630-6638
  Google Scholar
• 55. Wharton C.F., Pietroni R.: Polyarteritis after influenza vaccination.Br. Med. J., 1974; 2: 331-332
  Google Scholar
• 56. Więsik-Szewczyk E., Łącki J.K., Chwalińska-Sadowska H.: Shouldwe vaccinate patients with systemic lupus? Pol. Merkur. Lekarski.,2007; 23: 395-398
  Google Scholar
• 57. Więsik-Szewczyk E., Romanowska M., Mielnik P., ChwalińskaSadowskaH., Brydak L.B., Olesińska M., Ząbek J.: Anti-influenza vaccinationin systemic lupus erythematosus patients: an analysis ofspecific humoral response and vaccination safety. Clin. Rheumatol.,2010; 29: 605-613
  Google Scholar
• 58. Wraith D.C., Goldman M., Lambert P.H.: Vaccination and autoimmunediseases: what is the evidence? Lancet, 2003; 362: 1659-1666
  Google Scholar
• 59. Zhang J., Delzell E., Xie F., Baddley J.W., Spettell C., McmahanR.M., Fernandes J., Chen L., Winthrop K., Curtis J.: The use, safety,and effectiveness of herpes zoster vaccination in individuals withinflammatory and autoimmune diseases: a longitudinal observationalstudy. Arthritis Res. Ther., 2011; 13: R174
  Google Scholar

Full text